$0.77
6.42% yesterday
Nasdaq, Dec 24, 09:50 pm CET
ISIN
IL0011319527
Symbol
ENLV

Enlivex Therapeutics Ltd Stock price

$0.77
-0.25 24.22% 1M
-0.42 35.04% 6M
-0.40 33.93% YTD
-0.46 37.15% 1Y
-3.12 80.13% 3Y
-9.67 92.60% 5Y
-168.43 99.54% 10Y
-335.23 99.77% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
-0.05 6.42%
ISIN
IL0011319527
Symbol
ENLV
Industry

Key metrics

Basic
Market capitalization
$20.1m
Enterprise Value
$1.9m
Net debt
positive
Cash
$18.2m
Shares outstanding
24.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.2
Financial Health
Equity Ratio
85.2%
Return on Equity
-63.7%
ROCE
-81.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-14.3m | -
EBIT
$-14.6m | $-12.4m
Net Income
$-12.7m | $-12.8m
Free Cash Flow
$-12.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
7.2% | -
EBIT
9.5% | 20.5%
Net Income
32.9% | 15.0%
Free Cash Flow
16.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.6
FCF per Share
$-0.5
Short interest
0.5%
Employees
71
Rev per Employee
$0.0
Show more

Is Enlivex Therapeutics Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Enlivex Therapeutics Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Enlivex Therapeutics Ltd forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Enlivex Therapeutics Ltd forecast:

Buy
75%
Hold
25%

Financial data from Enlivex Therapeutics Ltd

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.03 5.03
12% 12%
-
- Research and Development Expense 9.59 9.59
18% 18%
-
-14 -14
7% 7%
-
- Depreciation and Amortization 0.29 0.29
59% 59%
-
EBIT (Operating Income) EBIT -15 -15
9% 9%
-
Net Profit -13 -13
33% 33%
-

In millions USD.

Don't miss a Thing! We will send you all news about Enlivex Therapeutics Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Enlivex Therapeutics Ltd Stock News

Neutral
GlobeNewsWire
21 days ago
Nes-Ziona, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), today announced that it will host a virtual fireside chat on Thursday, December 11, 2025 at 11:00 am ET.
Neutral
PRNewsWire
about one month ago
Enlivex Announced today $212,000,000 private placement to initiate world's first prediction markets digital asset treasury strategy, via RAIN token accumulation NESS ZIONA, Israel , Nov. 24, 2025 /PRNewswire/ -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV) today announced the appointment of Mr.
Neutral
GlobeNewsWire
about one month ago
- Upon the closing of the private placement, Enlivex will adopt the world's first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation. - RAIN is a fully decentralized predictions and options protocol that redefines predictive market ecosystems and provides a powerful platform for on-chain market creation - built for transparency, automation, and community ...
More Enlivex Therapeutics Ltd News

Company Profile

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.

Head office Israel
CEO Dr. Hershkovitz
Employees 71
Founded 2012
Website www.enlivex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today